T1	Claim 1 158	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
T2	MajorClaim 159 244	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
T3	Claim 409 475	Le(y) is an attractive target since it is expressed by most NSCLC.
T5	Premise 476 617	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
T6	Premise 1262 1417	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
T7	Premise 1419 1450	Toxicity was mild in both arms.
T8	Premise 1451 1478	QOL analyses favored Arm A.
T9	Claim 1479 1582	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
R1	Support Arg1:T5 Arg2:T9	
R2	Support Arg1:T8 Arg2:T9	
R3	Support Arg1:T7 Arg2:T9	
R4	Support Arg1:T6 Arg2:T9	
